Bivatuzumab

Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells[1].

Product Specifications

CAS Number

[214559-60-1]

Product Name Alternative

BIWA 4; Anti-CD44 Recombinant Antibody

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bivatuzumab.html

Purity

99.82

Solubility

10 mM in DMSO

Smiles

[Bivatuzumab]

Molecular Weight

(143.22 kDa)

References & Citations

[1]Leuci V, et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology. 2018 Feb 15;7 (5) :e1423167.

Shipping Conditions

Dry Ice

Storage Conditions

Store at -80°C for 2 years

Scientific Category

Inhibitory Antibodies

Clinical Information

Phase 1

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

E55P5370 50 µg

SA/Streptavidin Protein, HRP

Ask

View Details

CRM9740-01 15 nmol

CERS2 siRNA (Mouse)

Ask

View Details

CRM9740-02 30 nmol

CERS2 siRNA (Mouse)

Ask

View Details

SI013674B 1 Each

Human RGMA Pre-designed siRNA Set B

Ask

View Details

TA807041 100 µL

HMG20A Mouse Monoclonal Antibody [Clone ID: OTI5E3]

Ask

View Details

MBS2525470-01 0.02 mL

PTRH2 Polyclonal Antibody

Ask

View Details